Skip to main content
. 2014 May 6;9(5):e96671. doi: 10.1371/journal.pone.0096671

Figure 3. Pre-validation of urinary PDGFRB as a biomarker for predicting the recurrence of NMIBC.

Figure 3

(A) Comparison of the level of urinary PDGFRB in relapsed (n = 68) and relapse-free (n = 117) patients with NMIBC. The level of urinary PDGFRB was significantly lower in the patients with recurrence than those without recurrence (P<0.001). (B) The receiver operating characteristics (ROC) curve of urinary PDGFRB. The AUC was 0.826 (95% CI, 0.768 to 0.884). (C) The AUC of age, tumor size, and tumor number combined was 0.636 (95% CI, 0.552 to 0.721). (D) Inclusion of PDGFRB in this model increased the AUC to 0.862 (95% CI, 0.809 to 0.914).